Abstract-We first discuss several key technical issues associated with quantitative dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), and then provide examples of DCE-MRI in oncology. In particular, we examine the importance of both active and passive delivery of the contrast agent to the tissue under investigation, and repeatability/reproducibility in DCE-MRI studies. We then discuss examples of how DCE-MRI can assist in assessing and predicting therapeutic response in the neoadjuvant setting.
function (AIF). The AIF is a measure of the contrast agent concentration in the plasma, and is a necessary component for quantitative modeling as it provides the "input" to the system. The AIF can be measured via blood sampling, but this requires frequent, rapid sampling which is often uncomfortable in the clinical setting, and unrealistic in the preclinical setting given the small blood volume of the mice most frequently used in such studies. An alternative to blood sampling is the use of an image-derived AIF, but the difficultly associated with this approach is two-fold. First, a major vessel must be visible in the desired field of view and this is not always feasible given the region of interest. Secondly, the AIF displays rapid uptake and washout of the contrast agent; thus, in order to capture the relevant curve characteristics, the temporal resolution must be sufficiently fast. Unfortunately, this necessarily limits the spatial resolution of the acquisition. A common approach to avoid individual AIF acquisition is to employ a population AIF, whereby a similarly situated population of patients is utilized to generate an average AIF, which can then be applied to future patients [2] [3] [4] [5] [6] [7] . This eliminates the need to measure the individual AIF and allows for increased spatial resolution. Loveless et al. demonstrated that, in the preclinical setting, use of a population AIF did not significantly alter quantitative results as compared to the patient-specific AIF [4] . Parker et al. [7] and Li et al. [3] demonstrated similar results in the clinical setting, wherein using a population AIF increased the reproducibility of the quantitative parameters. Another commonly utilized approach which eliminates the need to acquire a patient-specific AIF is the reference region (RR) approach [8] [9] [10] . The RR approach utilizes a wellcharacterized tissue, such as muscle, to provide a second differential equation describing contrast agent concentration compartmentalization over time. This second equation allows for the elimination of the AIF, and results in a solution for the ROI that depends on the characteristics of the reference region.
Each of the above mentioned methods have their own strengths and weaknesses and care must be taken to select a method that is appropriate for the experiment at hand. The choice in input function is frequently determined by 1) the presence of a feeding vessel in the field of view, and 2) the required spatial resolution of the experiment. If high spatial resolution data is needed, this precludes the acquisition of high temporal resolution data so that a population averaged AIF or reference region approach is warranted. This is also the case if a feeding vessel is not available in the field of view. However, if high spatial resolution data is not required and a feeding vessel is available in the field of view, then direct measurement of the AIF is possible.
B. Incorporating the Effects of Contrast Agent Diffusion
Another point of consideration in quantitative DCE-MRI analysis is that the delivery of contrast agent (CA) to the region under study may not be done so actively; that is, the contrast agent may arrive by passive diffusion. Standard quantitative approaches, such as the Tofts-Kety model [1] , do not consider the effect of extravascular diffusion of the CA. However, diffusion has the potential to have a significant effect on contrast agent distribution and the observed pharmacokinetics in heterogeneous regions, as is often the case in tumor-bearing tissues that typically possess much variation in vascularity and necrosis. Acknowledgment of this shortcoming has led to the development of approaches to account for inter-and intravoxel CA diffusion. Pellerin et al. developed a finite difference model to analyze the effect of inter-voxel CA diffusion on quantitative DCE analysis [11] . Their model that incorporated inter-voxel diffusion by assigning domain diffusion coefficients, allowed for quantitative analysis of K trans and v e in the presence of diffusion. When analyzing DCE-MRI data in a xenograft model, the standard ToftsKety method resulted in unphysiological values of v e ; however, the results showed an improvement in the data when diffusion was considered. Fluckiger et al. worked to improve the practicality of this approach, by developing a less computationally intensive algorithm to include the effects of inter-voxel diffusion [12] . Their "diffusion compensated" Tofts-Kety model allowed for voxel-specific diffusion coefficients that were not dependent on the surrounding voxels; the model showed improved results over the standard Tofts-Kety model. Jia et al. utilized a factor termed the contrast agent diffusion coefficient (CDC) to evaluate diffusion in colorectal liver metastases [13] . The approach consisted of evaluating the rate of gradient decrease in the signal intensity of similarly-behaving regions. Their work showed that the CDC was a repeatable value which was able to describe the heterogeneity of the tissue. There is a growing awareness in the field that passive diffusion of contrast agent in the region under investigation can adversely affect the estimate of pharmacokinetic parameters. As these are the very parameters that have been shown to be of use in clinical studies, maximizing the accuracy with which they can be attained is of great import. Thus, the effects of contrast agent should be accounted for in certain settings. Of course, the precision at which these measurements can be made is also of great relevance.
III. REPEATABILITY AND REPRODUCIBILITY OF DCE-MRI
With the increasing use of DCE-MRI to characterize specific aspects of tumor physiology, it is imperative to assess the reproducibility in order to gain an understanding of the expected error within each imaging measurement. An example of DCE-MRI test-retest is shown in Figure 1 in which K trans parametric maps of a central tumor slice are displayed for two separate imaging sessions (within one week) of a patient with breast cancer. K trans was calculated by fitting the dynamic signal intensity for each voxel using the standard Tofts-Kety model [1] . The importance of such data is that one wants to be able to establish the range outside of which any observed changes can be safely assumed to be due to changes in biology and not errors in the measurement process. In the figure it is clear that, in this patient, while the trends are quite similar the absolute values of the pixels are different. Repeatability and reproducibility analyses attempt to characterize this issue. Two values of particular interest when assessing reproducibility are the repeatability coefficient (r) and the 95% confidence interval (CI) of the mean; these statistical values are useful in, for example, a treatment response study as they define a level above which a significant change due to therapy can be inferred. The repeatability coefficient r defines the expected limit of variability between two scans on the same subject in 95% of the cases. More specifically, this value defines the difference between scans that can be attributed to measurement error as opposed to physiological changes in an individual. The 95% CI provides a reproducibility measurement of the group mean for any specific parameter. The within-subject coefficient of variation (wCV) has also been used to evaluate reproducibility as it provides a measure of the variability within subjects; however, it is not as useful as r or 95% CI when interpreting treatment response data. Table 1 (next page) summarizes the reproducibility results from several clinical and preclinical DCE-MRI studies in various types of tumors [14] [15] [16] [17] [18] . The reproducibility statistics for K trans seem to vary among the clinical and preclinical studies; for example, r was 0.26 min -1 in patients [14] , and ranged from 0.005 min -1 to 0.22 min -1 in rodent models of cancer [16] [17] [18] . This large range could be due to several variables, although it is most likely due to differences in data acquisition and analysis protocols. Ferrier et al. [17] and Barnes et al. [16] used a power injector for contrast agent administration whereas Galbraith et al. [14] and Yankeelov et al. [18] used manual injections. Galbraith et al. hypothesized that using a power injection to administer the contrast agent would significantly improve reproducibility, and the data in Table 1 (next page) support this hypothesis.
The variability associated with v e appears to be less sensitive to the mechanism of contrast agent injection, as v e had better reproducibility than K trans in all but one of the studies summarized in Table 1 . For example, the 95% CI ranged between ± 6.0% and ± 7.3%, while the wCV ranged between 6.2% and 8.5% [14] [15] [16] . Reproducibility in terms of r and wCV is similar between K trans and v e in [18] . In addition to measuring reproducibility at a single institution, it is also imperative to investigate the error associated with DCE-MRI protocols across institutions in order to facilitate multisite trials. There have been only limited efforts at determining multisite reproducibility for quantitative DCE-MRI protocols and this is the subject of several ongoing efforts. Importantly, such investigations are also ongoing in other imaging modalities including FDG-PET. Only when such statistical issues are determined can we truly have confidence that the measurement is ready for, e.g., multi-site clinical trials. As there has been much success at single site trials, this is a problem to address.
IV. CLINICAL APPLICATIONS IN THE NEOADJUVANT SETTING
In the neoadjuvant setting, cancer patients receive therapy to reduce tumor burden to a size more amenable to surgery. Neoadjuvant therapy also provides an opportunity to observe tumor sensitivity to a particular regimen [19] . However, if it were possible to determine that the primary tumor is unresponsive, the treatment could be changed to another, potentially more effective approach thereby avoiding unnecessary side effects and toxicities. DCE-MRI is one such method that has been proposed to accomplish this task. For example, the I-SPY TRIAL [20] scanned 216 women with breast cancers at four time points: prior to the start of anthracycline-cyclophosphamide (AC) chemotherapy, prior to the second cycle of AC chemotherapy, between AC treatment and taxane therapy, and just prior to surgery. This study showed that the rate of change of the tumor volume and the signal enhancement rate (SER) between therapeutic regimens yielded an area under receiver operating characteristic curve (AUC) of 0.72 and 0.71, respectively.
Other studies have employed more quantitative DCE-MRI pharmacokinetic models to investigate the ability to predict eventual response in breast cancer. Padhani et al. [21] performed DCE-MRI examinations in 25 patients with primary breast cancer before, after the first and after the second cycle of neoadjuvant chemotherapy (NAC) and investigated tumor size, K trans , v e , and k ep . Both tumor size and change in the range of the K trans histogram after two cycles of treatment were able to predict eventual response with AUCs of 0.93 and 0.94, respectively. Recently Li et al. [22] examined 28 patients using DCE-MRI at three time points: pretreatment, post-one cycle of NAC, and just prior to surgery. Semi-quantitative and quantitative physiological parameters were evaluated, including tumor longest dimension, tumor volume, initial area under the curve, SER and SER related parameters, K trans , v e , k ep , plasma volume fraction (v p ), and the average intracellular water lifetime of a water molecule (τ i ), using three pharmacokinetic models. Among all the parameters, the changes in the SER washout volume and k ep were the best predictors of pathologic complete responders after one cycle of NAC. The SER washout volume yielded an AUC of 0.75, and k ep yielded a maximum estimated AUC of 0.78. Figure 2 shows the k ep maps superimposed on the post-contrast DCE-MRI data at the pre-NAC (1st column), post-1 cycle of NAC (2nd column), and post all cycles of NAC (3rd column) time points for one representative patient achieving pathological complete response (pCR). Note that the mean k ep has decreased from 0.39 min -1 at baseline to 0.28 min -1 after one cycle of therapy. Li et al. also combined the DCE-MRI and diffusion weighted MRI (DW-MRI) data using a simple ratio r, repeatability coefficient, CI, confidence interval; wCV, withinsubject coefficient of variation (k ep /ADC, where ADC is the apparent diffusion coefficient from the DW-MRI data) and showed that the integrated data have a better ability to predict treatment response [23] .
There also are studies investigating the predictive ability of the DCE-MRI parameters on other cancers for which neoadjuvant therapy is appropriate. Kim et al. [24] performed DCE-MRI on 33 patients with head and neck squamous cell carcinomas before neoadjuvant chemoradiation. K trans , v e , and τ i were estimated. It was reported that the average pretreatment K trans was higher in patients achieving a complete response than in those patients who saw a partial response (p = 0.001). In the study of Guo et al. [25] , 69 patients with osteosarcoma were examined using DCE-MRI at week 0, week 9, and week 12. 
